Biocartis NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company, announces that it has placed its 1,000th Idylla(TM) instrument. The instrument was placed in the US with Diagnostic Medicine Institute at Geisinger.
The Geisinger Medical Center in Danville, Pennsylvania (US) is one of the main hospitals in the Geisinger which covers 13 hospital campuses, two research centers and close to 30 specialties, including an advanced cancer institute in the Pennsylvania and New Jersey regions. Geisinger is one of the largest health service organizations in the US, serving millions of patients throughout Pennsylvania and New Jersey
Herman Verrelst, CEO Biocartis, commented: “We are very proud that we could place our 1,000th Idylla(TM) instrument with Geisinger which is one of the oncology practices in the US and an important business partner for Biocartis going forward. Crossing the 1,000 mark is an important milestone in the global commercial roll-out of the Idylla(TM) platform and further strengthens our position in partnership discussions.”
Yi Ding, M.D., Ph.D., System and Core Lab Director, Diagnostic Medicine Institute at Geisinger, reacted: “Oncology is one of the key specialist areas for Geisinger, with the Diagnostic Medicine Institute at Geisinger being a player in precision medicine. We are excited about using the Idylla(TM) technology as it is fast and easy to use and delivers highly accurate results.”
Related Reports and Monitors
Nanopore Sequencing 2019 – Patent Landscape Analysis
CRISPR Technology & Market Overview: from Lab to Industry 2018
Market & Technology